Vecura
PricingSolutions
Resources
Contact us
Vecura

Product

  • Solutions
  • Pricing

Company

  • Contact us

Resources

  • Updates
  • News
  • Insights
  • Use Cases
  • Community

Legal

  • Privacy Policy
  • Terms of Service
  • Trust Center

© 2026 NYB AI. All rights reserved.

All systems operational
Vecura
PricingSolutions
Resources
Contact us
Back to updates

HERGAI: Structure-Based hERG Inhibition Prediction Now Available on Vecura

This integration allows drug discovery researchers to assess hERG inhibition liability for small molecules directly within Vecura, utilizing a high-performance structure-based AI pipeline without the need for manual setup or complex infrastructure.

May 12, 2026hERGAI
hERGAI
hERGAI is now available on Vecura

What is HERGAI?

HERGAI is a specialized, structure-based AI classifier designed to predict the hERG potassium-channel inhibition liability of small molecules. By utilizing a fixed hERG receptor structure (7CN1) and AutoDock Vina, the model docks ligands and generates Protein-Ligand Extended Connectivity (PLEC) fingerprints, which are processed by a 4-model stacking ensemble. It helps users quickly assess whether a drug candidate poses a risk of cardiotoxicity. It is especially useful for drug discovery teams conducting early-stage lead optimization or pre-clinical ADMET profiling.

What can users do with HERGAI on Vecura?

With HERGAI on Vecura, users can:

  • Predict hERG inhibition probability for a list of SMILES strings.
  • Obtain a clear binary "Active" or "Inactive" cardiotoxicity label.
  • Streamline the ADMET profiling process by bypassing complex, manual docking workflows.
  • Leverage a benchmarked, high-performance structure-based method published in the Journal of Cheminformatics.

What the output means

The output provides a comprehensive prediction report, including the headline dnn_sc_prob (the final probability of being an hERG inhibitor), binary classification results based on a calibrated threshold, and individual probabilities from base classifiers (Random Forest, XGBoost, and a Keras DNN).

This output should be used to support scientific decision-making. It does not replace experimental validation.

Why this matters

The human Ether-a-go-go-Related Gene (hERG) potassium channel is a critical anti-target in drug discovery, as its blockade is a primary cause of drug-induced QT prolongation and lethal arrhythmias. Consequently, regulatory bodies require thorough screening of drug candidates for this liability.

Traditionally, structure-based docking approaches can be computationally intensive and complex to standardize. HERGAI provides a robust, pre-configured pipeline that simplifies this assessment, enabling researchers to identify potential cardiotoxicity risks earlier in the design cycle and prioritize safer chemical series for further development.

  • Developed by: vktrannguyen
  • Source: Official GitHub Repository
  • Reference: Journal of Cheminformatics (2025)

Try hERGAI on Vecura.

Open the model workspace and start evaluating it with your own inputs.

Try model

Topics

hERGcardiotoxicityADMETdrug-discoverysmall-moleculePLECstructure-basedclassification

On this page

What is HERGAI?What can users do with HERGAI on Vecura?What the output meansWhy this matters

Try hERGAI on Vecura.

Try model

Related posts

Accelerate Your Solubility Screening: fastsolv is Now Integrated into Vecura

Jul 27, 2026

Protein Pocket Detection with SiteFerret Now Available on Vecura

Jul 24, 2026

Accelerate Drug Discovery: PocketGen is Now Available on Vecura

Jul 20, 2026

Vecura

Product

  • Solutions
  • Pricing

Company

  • Contact us

Resources

  • Updates
  • News
  • Insights
  • Use Cases
  • Community

Legal

  • Privacy Policy
  • Terms of Service
  • Trust Center

© 2026 NYB AI. All rights reserved.

All systems operational